Farooqi Shaheer, Tebha Sameer Saleem, Qamar Mohammad Aadil, Singh Spencer, Alfawares Yara, Ramanathan Vishan, Haider Ali S, Ferini Gianluca, Sharma Mayur, Umana Giuseppe E, Aoun Salah G, Palmisciano Paolo
Medical College, Ziauddin University, Karachi, Pakistan.
Department of Neurosurgery and Neurology, Jinnah Medical and Dental College, Karachi, Pakistan.
World Neurosurg. 2023 May;173:237-250.e8. doi: 10.1016/j.wneu.2023.02.098. Epub 2023 Feb 28.
Intramedullary spinal cord ependymomas (IMSCEs) are rare tumors that mostly occur in adults. Management strategies and related outcomes are heterogeneously reported across the literature, demanding a comprehensive analysis to standardize guidelines. We performed a systematic review of the literature on IMSCEs.
A literature search was conducted using 6 databases from inception up to July 28, 2022. Studies with data on clinical characteristics, management strategies, and related outcomes in adult patients with histopathologically confirmed IMSCEs were pooled and analyzed.
The analysis included 69 studies comprising 457 patients (52.7% males). Mean age was 42.4 ± 7.4 years. Sensory deficit (58.0%) was the most prevalent symptom, followed by radicular pain (50.5%). Tumors mostly involved the cervical (64.4%) or thoracic (18.8%) spinal cord and were mostly World Health Organization grade II (80.5%) and classic subtype (72.4%). Gross total resection was performed in most cases (83.4%), with adjuvant radiotherapy delivered in 10.5% of cases. Progression-free survival ≥2 years was reported in 61.1% of cases, and tumor recurrence or progression was reported in only 7.0% of the patients. At last follow-up, 97.4% of patients were alive.
IMSCEs are uncommon tumors that frequently manifest with debilitating symptoms that require surgical treatment. When feasible, gross total resection may be pursued to improve the patient's functional status and prevent tumor progression, with adjuvant radiotherapy required only in some more aggressive grade III lesions. Future studies should investigate different growth patterns and prognoses based on different IMSCE subtypes.
脊髓髓内室管膜瘤(IMSCEs)是罕见肿瘤,大多发生于成人。文献中关于其治疗策略及相关结果的报道存在差异,需要进行全面分析以规范指南。我们对有关IMSCEs的文献进行了系统综述。
使用6个数据库进行文献检索,检索时间从数据库建立至2022年7月28日。汇总并分析了有关组织病理学确诊的成人IMSCEs患者的临床特征、治疗策略及相关结果的数据的研究。
分析纳入69项研究,共457例患者(男性占52.7%)。平均年龄为42.4±7.4岁。感觉障碍(58.0%)是最常见症状,其次是神经根性疼痛(50.5%)。肿瘤大多累及颈髓(64.4%)或胸髓(18.8%),大多为世界卫生组织二级(80.5%)且为经典亚型(72.4%)。大多数病例(83.4%)进行了全切除,10.5%的病例接受了辅助放疗。61.1%的病例报告无进展生存期≥2年,仅7.0%的患者报告有肿瘤复发或进展。在最后一次随访时,97.4%的患者存活。
IMSCEs是罕见肿瘤,常表现为需要手术治疗的使人衰弱的症状。可行时,可进行全切除以改善患者功能状态并预防肿瘤进展,仅在一些侵袭性更强的三级病变中需要辅助放疗。未来研究应基于不同的IMSCE亚型研究不同的生长模式和预后。